CAS No. |
630-94-4 |
英文名称 |
methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate |
别名 |
corynoxeine;(7R,16E,20α)-16,17,18,19-Tetradehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester;(alphaE,1'R,6'R,7'S,8'aS)-6'-Ethenyl-1,2,2',3',6',7',8',8'a-octahydro-alpha-(methoxymethylene)-2-oxospiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid methyl ester;16,17,18,19-Tetradehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester;Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-aceticacid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-a-(methoxymethylene)-2-oxo-, methyl ester, (aE,1'R,6'R,7'S,8'aS)-;Corynoxeine, 99.9%;Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-α-(methoxymethylene)-2-oxo-, methyl ester, (αE,1'R,6'R,7'S,8'aS)-;corynoxeine USP/EP/BP |
标准英文名 |
methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate |
分子式 |
C22H26N2O4 |
分子量 |
382.46
|
精确分子量 |
382.19
|
SMILES |
C=C[C@H]1CN2CC[C@]3(C(=O)NC4=CC=CC=C43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC |
标准SMILES |
CO/C=C(\[C@H]1C[C@@H]2N(C[C@@H]1C=C)CC[C@]12C2=CC=CC=C2NC1=O)/C(=O)OC |
用途 |
Corynoxeine exhibits vasodilatory effects on aortic rings of hypertensive rats, demonstrating peripheral vasodilation, negative inotropic activity, and antihypertensive effects; it can be used in the preparation of vasodilator and antihypertensive drugs. It reduces cardiac afterload and myocardial contractility, thereby decreasing myocardial oxygen consumption, and is applicable in the development of anti-anginal medications, particularly for acute angina treatment. Corynoxeine shows negative inotropic effects and can be used to formulate drugs for ventricular tachycardia. It also elevates the excitation threshold of ventricular myocardium, making it suitable for the preparation of anti-ventricular arrhythmic agents. Additionally, corynoxeine acts as a potent inhibitor of ERK1/ERK2 activation in PDGF-BB-induced vascular smooth muscle cell (VSMC) proliferation, effectively suppressing VSMC proliferation and DNA synthesis without cytotoxicity. It is also used for pharmacological research, content determination, and compound identification. Pharmacologically, it inhibits the respiratory center and isolated intestinal motility, stimulates isolated rat uterine contraction, lowers blood pressure, inhibits platelet aggregation, promotes disaggregation of already aggregated platelets, and improves erythrocyte deformability by protecting against impairing factors. Clinically, it is used in the treatment of hypertension, showing efficacy in stages I and II hypertension. |
InChIKey |
MUVGVMUWMAGNSY-KAXDATADSA-N |